Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 3/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13399161 | 0.91 | PTGER2 (0.56) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5042997 | 0.84 | TAS2R14 (0.49) | PTGER2TAS2R14CA12CA1CA2 | |
| SCHEMBL5134042 | 0.81 | FFAR1 (0.53) | TAS2R14CA12CA1CA2CA4 | |
| SCHEMBL13398755 | 0.81 | PTGER2 (0.71) | PTGER2TAS2R14CA12CA1CA2 | |
| SCHEMBL27547782 | 0.80 | FFAR1 (0.47) | TAS2R14CA12CA1CA2CA4 | |
| SCHEMBL13399398 | 0.80 | PTGER2 (0.58) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13399316 | 0.79 | TAS2R14 (0.48) | PTGER2TAS2R14CA12CA1CA2 | |
| SCHEMBL4943884 | 0.79 | CA12 (0.56) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5726867 | 0.78 | TLR7 (0.45) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13398736 | 0.78 | PTGER2 (0.51) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | PTGER2 1/4885TAS2R14 2957/4885CA12 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.